FACSIMILE COVER SHEET
CONFIDENTIAL AND PRIVILEGED

RECEIVED
CENTRAL FAX CENTER

APR 2 1 2004

Perkins Coie

101 Jefferson Drive
Menlo Park, CA 94025-1114
PHONE: 650.838.4300
FAX: 650.838.4350
www.perkinscoie.com

DATE: **April 21, 2004**   COVER SHEET & **1**   PAGE(S)

ORIGINAL DOCUMENT(S) WILL BE: ☐ SENT TO YOU   ☑ HELD IN OUR FILES

SENDER:	TELEPHONE:	FACSIMILE:
LeeAnn Gorthey	650-838-4403	650-838-4350

RECIPIENT:	COMPANY:	TELEPHONE:	FACSIMILE:
Examiner J. Epps-Ford	*USPTO* *Art Unit 1635*	*(571) 272-0757*	*(571)273-0757*

RE: **US Serial No. 09/826,519**
   Atty Docket No. 1565.006 (52456.8017.US01)

Dear Examiner Epps-Ford,

In response to your telephone request this morning, I have enclosed a listing of the pending claims in the above-referenced application, as of the last amendment to the claims (which was filed on February 11, 2003). You are correct in that there are now three claims pending. Please let me know if you need anything further.

Best regards,

LeeAnn Gorthey, Ph.D.
Patent Agent
Perkins Coie LLP
Reg. No. 37,337

ANCHORAGE · BEIJING · BELLEVUE · BOISE · CHICAGO · DENVER · HONG KONG · LOS ANGELES
MENLO PARK · OLYMPIA · PORTLAND · SAN FRANCISCO · SEATTLE · SPOKANE · WASHINGTON, D.C.
Perkins Coie LLP (Perkins Coie LLC in Illinois)

Status of claims in USSN 09/826,519
per response filed February 11, 2003

1-7. (Cancelled)

8. (Previously presented)   A chimeric oligonucleotide having the formula
$5'–W–X^1–Y–X^2–Z–3'$, wherein

W represents a 5'-O-alkyl nucleotide;

each of X^1 and X^2 represents a block of seven to twelve phosphodiester-linked 2'-O-alkyl ribonucleotides;

Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides; and

Z represents a blocking group effective to block nuclease activity at the 3' end of the oligonucleotide; and

$X^1—Y—X^2$ has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 9 and 10.

9-21. (Cancelled)

22. (New)   The oligonucleotide of claim 8, wherein $X^1—Y—X^2$ has the nucleotide sequence SEQ ID NO: 9.

23. (New)   The oligonucleotide of claim 8, wherein $X^1—Y—X^2$ has the nucleotide sequence SEQ ID NO: 10.